



September 11, 2019

CURRENT PRICE: \$44.72
RATING: HOLD
PRICE TARGET: N/A
CURRENT YIELD: 7.5%

EPS Estimates - Non-GAAP

	DEC 18A	DEC 19E
1Q	\$1.00 A	\$0.60A
2Q	\$0.99 A	\$1.07A
3Q	\$1.03 A	\$1.04
4Q	\$0.66 A	\$0.88
	\$3.68	\$3.59

Trading Data

52-WEEK PRICE RANGE: **\$66.04 - \$42.40**
SHARES OUTSTANDING: **1,870(M)**
MARKET CAP: **\$83.6(B)**
AVG. DAILY TRADING VOLUME: **10.5(M)**
S&P 500: **3,001**

Valuation Data

BOOK VALUE: **\$7.74**
PRICE TO BOOK: **5.8x**
DIVIDEND: **\$3.36**

Altria Corp (NYSE: MO)

2Q19 earnings & JUUL controversy

Highlights

- 2Q19 earnings of \$1.07/share vs. \$0.99/share during 2Q18
- Increased annual dividend 5%
- Potential merger with Philip Morris
- FDA proposes ban on flavored e-vapes
- Maintain HOLD rating

Investment Thesis

Altria Corp (MO-\$44.72), formerly known as Philip Morris, is the largest US tobacco company. MO is focused on the US domestic tobacco business and has seen year-over-year revenue growth, on a pro-forma basis. Going forward management intends to grow earnings through revenue/cash flow growth, share repurchases, and cost reductions. Earnings growth may generate dividend increases in the future. MO's stock pays a current dividend yield of 7.5%.

Company Summary

Altria Group, headquartered in Richmond VA, is the parent company of Philip Morris USA, US Smokeless Tobacco, John Middleton, Ste. Michelle Estate Wineries, and Philip Morris Capital Corp (PMCC). The company operates five segments: domestic cigarettes, smokeless tobacco products, machine made cigars, wineries, and financial services/real estate. The company has 9,900 employees located throughout the US. Philip Morris USA manufactures and sells cigarettes, and other tobacco products, in the US. This unit's cigarette brands include "Marlboro" (#1 in US market share), "Benson & Hedges", "Parliament", "Basic" and "Virginia Slims". This business gives MO approximately a 50% market share of the US cigarette market. Through 12/31/18 Philip Morris USA generated approximately 87.9% of overall revenues, or \$22.3 billion. During 2009 MO completed its purchase of US Tobacco (Skoal/Copenhagen brands & Ste. Michele Wines) and currently gives MO 53.9% of the smokeless tobacco market share.

For Important Disclosure information regarding the Firm's rating system, valuation methods and potential conflicts of interest, please refer to the last two pages of this report.



EQUITY RESEARCH

Business Overview

MO is the largest cigarette manufacturer in the US. In 2007 the company purchased the John Middleton Co which sells and manufactures machine-made cigars (Black & Mild)/pipe tobacco. The Smokeable business unit (includes cigarettes/cigars) generated 87.9% of MO's revenues, or \$22.3 billion during FY18. PMCC owns a portfolio of leveraged/direct finance leases and produced less than 1% of revenues. MO also owns approximately a 10.2% economic equity interest, with voting rights, in Anheuser-Busch InBev (BUD-\$94.27). Over the past twenty years MO at one time owned, or acquired, Miller Brewing, Nabisco, Kraft, and Jacobs Suchard AG. These businesses were subsequently either sold or spun-off. During the past few years the company spun-off Kraft Foods (KHC-\$29.28) and Philip Morris Intl (PM-\$75.07). To reduce its dependence of tobacco revenue streams, MO recently acquired equity stakes in JUUL Labs and Cronos (CRON-\$11.54).

Recent Earnings

MO reported 2Q19 diluted earnings of \$1.07/share vs. \$0.99/share during 2Q18. The 8.1% improvement, when comparing the two quarters, was due to higher Operating Company Income (OCI) income and return from equity investments, as well as lower income taxes. These were partly offset by higher interest expense (\$312 million vs. \$178 million) and a loss from Cronos related financial instruments (\$266 million). OCI improved in the Smokeable (+\$170 million) and Smokeless segments (+\$43 million), and more than offset a decline in the Wine segment (-\$2 million). Overall revenues increased to \$6.62 billion from \$6.31 billion and operating income rose to \$2.72 billion from \$2.50 billion. MO's 2Q19 adjusted earnings improved to \$1.10/share from \$1.01/share during 2Q18. This 8.9% increase was due to higher adjusted OCI in the Smokeable and Smokeless segments, higher adjusted earnings from its equity investment in Anheuser-Busch Inbev (BUD-\$94.27), and lower corporate spending which was partly offset by higher interest expense.

SEGMENT RESULTS

SMOKEABLE PRODUCTS: Reported OCI improved 7.7% to \$2.38 billion from \$2.20 billion because of higher pricing and lower costs (excluding health/litigation items). The gain was partly offset by higher resolution expenses and increased asset impairment/exit/implementation costs. When comparing the two quarters, adjusted OCI rose 11.0% to \$2.43 billion from \$2.19 billion due to higher prices and lower costs but were partially offset by higher resolution expenses. Adjusted OCI margins rose to 54.4% from 52.6%. Revenues increased by 5.5% to \$5.85 billion from \$5.55 billion.

MO's total cigarette shipments improved 0.3% to 27.36 billion sticks from 27.27 billion sticks. The increase came from trade inventory movements, and was partly offset by the overall industry's rate of decline and loss in MO's retail share. If adjusted for trade inventory movements, and other factors, then smokeable's cigarette



shipments fell by 6%. MO's overall cigarette retail market share decreased to 49.9% from 50.3% as Marlboro's was flat at 43.3%, Other Premium fell to 2.5% from 2.6%, and Discounts declined to 4.1% from 4.4%.

Total cigar shipments improved to 428 million sticks from 417 million sticks. The 2.6% increase occurred as Black & Mild's shipments rose to 425 million sticks from 414 million sticks, while Other's was flat at 3 million sticks.

SMOKELESS PRODUCTS: Reported OCI increased 11.4% to \$420 million from \$377 million due to higher product pricing, lower promotional investments and costs. These were partly offset by lower shipment volumes. Adjusted OCI improved 10.8% to \$422 million from \$381 million and adjusted OCI margins rose to 74.0% from 69.9%. Net revenues increased 4.0% to \$602 million from \$579 million because of higher pricing and lower promotional investments, partially offset by a decrease in shipment volumes.

Total smokeless product shipment volumes declined 3.6% to 208.0 million cans/packs due to the overall industry's rate of decline, trade inventory movements, and retail share loss. When adjusted for inventory movements this unit's shipment volumes fell 3.0%.

MO's overall smokeless market share decreased to 53.9% from 54.1%. While Copenhagen's market share rose to 34.6% from 34.3%, Others' improved to 3.5% from 3.4%, and Skoal's fell to 15.8% from 16.4%.

WINE SEGMENT: Reported and adjusted OCI decreased to \$19 million from \$27 million due to higher costs and an unfavorable premium mix. OCI margins fell to 11.9% from 16.7% and reported wine shipments rose 2.7% to 2.0 million cases. Revenues decreased slightly to \$165 million from \$166 million.

RECENT DEVELOPMENTS:

MO announced it was considering a merger-of-equals with Phillip Morris (MO-\$75.07) from which it spun-off several years ago. The merger is dependent on approvals from both Boards of Directors and needs regulatory approval from the US Government.

The Board of Directors recently raised the quarterly dividend to \$0.84/share from \$0.80/share.

Given recent news and deaths connected to e-vape product use, several states and Federal agencies announced investigations into the selling and health effects of e-vap products such as those sold by JUUL.



The Trump Administration expressed its desire to eliminate all flavored e-vapes in attempt to end underage use of the product. The FDA is proposing regulations requiring any flavored e-vape product, not including tobacco flavored, be removed from the market, until they apply and receive product approval from the FDA. Thus, the FDA may potentially regulate sales of all e-vape products in the US.

Potential future legislation is being considered to curb sales of JUUL products. San Francisco, CA is proposing legislation to prohibit e-vape sales. Michigan recently passed legislation forbidding flavored e-vape sales and the state of New York is considering a similar law. Earlier this year, MO purchased a 35% stake in JUUL.

As part of its share repurchase program, MO repurchased 3.7 million shares during 2Q19 and completed its \$2 billion share repurchase program. Additionally, the Board of Directors approved a new \$1 billion share repurchase program and expects completion by the end of 2020.

MO will acquire 80% ownership (\$372 million) of certain companies of the Burger Group which will commercialize “on!” oral nicotine products.

This past April, the FDA authorized the sale of Philip Morris’s (PM-\$75.07) IQOS heated tobacco systems in the US. MO anticipates selling this product throughout the US later this month. MO plans to initially introduce the product in the Atlanta GA market during 3Q19.

Thus far in 2019, 18 states and Washington DC increased the legal age to buy tobacco products to 21.

NEW DEBT INCURRED BY MO

To finance these acquisitions MO took a \$14.6 billion term loan from JPMorgan (JPM-\$117.19), with \$1.8 billion of the loan un-used and at an interest rate 100 bps above LIBOR, or ~3.5%. MO’s total debt will rise to \$26.4 billion from \$13 billion and MO’s debt/EBITDA ratio will rise to 2.7x from 1.3x. This additional debt will increase annual interest payments from \$500 million - \$600 million to over \$1.1 billion. To counter this interest expense increase, MO announced a new cost-cutting program aimed at reducing annual operating costs by \$575 million.

Due to the additional debt, S&P lowered MO’s credit rating to BBB from A- (with a steady outlook) and Moody’s cut its rating to a “negative outlook”. S&P believes FDA statements, about fighting underage use of e-vapes, creates uncertainty over JUUL’s long term valuation. Additionally, S&P said it “does not believe JUUL or Cronos will provide significant near term investment returns to Altria and will not allow MO to deleverage new debt levels over the near term.” S&P further said, while the JUUL/CRONOS investments will not be adding to the company’s profits over the near term, MO is paying for future growth-assuming JUUL & Cronos grow revenues.



EQUITY RESEARCH

Our Thoughts

MO had a good quarterly earnings report producing 2Q19 diluted earnings of \$1.07/share vs. \$0.99/share during 2Q18. The improvement came mainly from higher OCI income and equity investments, as well as lower income taxes. These were partly offset by higher interest expense and a loss from the Cronos related financial instruments. MO's 2Q19 adjusted earnings improved to \$1.10/share from \$1.01/share during 2Q18 was due to higher adjusted OCI in the Smokeable and Smokeless segments, higher returns from its equity investment in Anheuser-Busch Inbev (BUD-\$94.27), and lower corporate spending, partly offset by higher interest expense.

The stock has been under recent selling pressure as Wall Street questions the potential merger with Philip Morris (PM-\$75.07) and concerns over law makers moving against e-vape products, of which JUUL had a 78% US market share in 2018 while MO has a 35% stake in JUUL. Thus, investors' concerns are growing about MO's returns on its recent \$12.6 billion investment in JUUL.

To quell Wall Street's concerns, MO will need to prove they can grow overall revenues despite the cigarette industry's overall annual rate of decline of 4%-5%, overcome investor fears of increased balance sheet debt, and receive returns on investments in JUUL and Cronos (CRON-\$11.54). Assuming FDA approval, MO believes JUUL may contribute to its bottom line in 2020 while a contribution from CRON is unlikely until marijuana is legalized in the US. We anticipate more clarity on the JUUL regulatory situation during MO's 3Q earnings call. During 2Q19's earnings call, MO provided 2019 adjusted earnings guidance of \$4.15-\$4.27/share and stressed its goal of paying 80% of adjusted earnings as dividend to shareholders. Paying a current 7.5% dividend yield, we continue to rate this stock a HOLD.

Risks

There is no guarantee MO will improve earnings/cash flow. Declining US cigarette consumption/volumes may hurt the company's revenues and profits. Declining earnings from MO's three operating units pose a risk to the company. The ownership stakes in Cronos (CRON-\$) and JUUL may not produce enough profits to pay higher interest payments on subsequent debt incurred for these investments. Litigation/regulation risks and excise taxes threaten cigarette manufacturers. Rising interest rates/inflation, corporate tax rates, economic recessions, higher tobacco prices, increased gasoline prices, rising operating costs/debt expense, or tax issues could negatively impact MO's earnings. MO's stock may be adversely impacted by negative equity/credit markets, geopolitical events, wars, cyber hacking, terrorist attacks, and failure to comply with Sarbanes Oxley and generally accepted accounting guidelines.

Steven F. Marascia
Director of Research
Capitol Securities Management
804-612-9715




EQUITY RESEARCH

Altria Group, Inc.
(dollars in millions, except per share data)

	1Q18	2Q18	3Q18	4Q18	FY18	1Q19	2Q19	3Q19e	4Q19e	FY19e
Net revenues	\$6,108	\$6,305	\$6,837	\$6,114	\$25,364	\$5,628	\$6,619	\$6,798	\$ 5,993	\$25,038
Cost of sales	1,734	1,738	2,037	1,864	7,373	1,578	1,874	1,903	1,678	7,033
Excise taxes on products	1,438	1,426	1,545	1,328	5,737	1,239	1,426	1,529	1,348	5,542
Gross profit	2,936	3,141	3,255	2,922	12,254	2,811	3,319	3,366	2,967	12,463
Marketing, administration, & research costs	567	591	619	626	2,403	479	499	521	514	2,013
Exit cost/asset impairment	2	2	2	381	383	39	33	5	8	85
Operating companies income	2,367	2,548	2,638	1,915	9,468	2,293	2,787	2,840	2,445	10,365
Amortization of intangibles	5	5	20	8	38	8	8	17	12	45
General corporate expenses	46	45	61	163	315	46	62	52	55	215
Changes to MDLZ/PM tax-related receivables										
Adjustment to 3rd party guarantee accrual										
Corporate asset impairment/exit costs						1				1
Corporate exit cost										
Operating income	2,316	2,498	2,557	1,744	9,115	2,238	2,717	2,771	2,378	10,104
Restructuring charge										
Interest & other debt expense, net	166	179	159	162	665	384	312	382	379	1,457
Loss on early debt extinguishment										
Earnings from SABMiller equity investment	342	228	189	131	890	86	447	219	199	951
Other Income		9	21	3	34	1	15	5	8	28
Loss on AB InBev/SAB Miller business combination	33				33					
Loss on Cronos-related financial instruments						425	266			691
Earnings before income taxes	2,466	2,557	2,608	1,710	9,341	1,516	2,601	2,613	2,206	8,936
Income taxes	571	680	664	459	2,374	395	604	669	565	2,233
Net earnings (continuing ops.)	1,895	1,877	1,944	1,251	6,967	1,121	1,997	1,944	1,641	6,703
Earnings from discontinued ops.										
Earnings attributable to non-controlling interests	-1	-1	-1	-1	-4	-1	-1	-1	-1	-4
Net earnings	\$1,894	\$1,876	\$1,943	\$1,251	\$6,963	\$1,120	\$1,996	\$1,943	\$1,640	\$6,699
Net earnings attributable to Altria	\$1.00	\$0.99	\$1.03	\$0.66	\$3.68	\$0.60	\$1.07	\$1.04	\$0.88	\$3.59
Earnings per share	\$0.95	\$1.01	\$1.08	\$0.95	\$3.99	\$0.90	\$1.10	\$1.20	\$1.02	\$4.22
Continuing operations earnings per share	\$1.00	\$0.99	\$1.03	\$0.66	\$3.68	\$0.60	\$1.07	\$1.04	\$0.88	\$3.59

Important Disclosures

Daily ▶ MO Altria Group Incorporated C: 44.72 Chg 0.48



9/14/09 \$17.99 Initiate BUY
 5/18/10 Raised price target to \$23/share
 8/17/10 Raised price target to \$24/share
 11/16/10 Raised price target to \$26/share
 5/10/11 Raised price target to \$29/share
 2/28/12 Raised price target to \$31/share
 5/16/12 Raised price target to \$33/share
 8/31/12 Raised price target to \$36/share
 6/07/13 Raised price target to \$38/share
 6/24/14 Raised price target to \$44/share
 11/26/14 Reduced rating to HOLD
 Ratings:
 Buy: B
 Hold: H
 Sell: S

Steven Marascia certifies, with respect to the companies or securities that he analyzes, that (1) the views expressed in this report accurately reflect his personal views about all of the subject companies and securities and (2) no part of his compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

Stock ratings used in this report are defined as follows:

- (1) Buy – The stock's total return including dividends is expected to exceed the industry or market average by at least 10% over the next twelve months.
- (2) Hold – The stock's total return including dividends is expected to be in line with the industry or market average of +/- 10% over the next twelve months.
- (3) Sell – The Stock's total return including dividends is expected to be below the industry or market average by 10% or more over the next twelve months.

The distribution of investment ratings for all companies in our coverage universe are as follows: (1) 33.3%, (2) 66.7%, (3) 0%

The distribution of investment ratings used for companies whom we have performed banking services in the last 12 months are (1)100%, (2) 0%, (3) 0%

Capitol Securities Management's Investment Banking/Public Finance unit has not received compensation for investment banking services from the subject company in the past 12 months. Nor does it expect to receive, or intend to seek compensation for, investment banking services from the subject company in the next 3 months.

No affiliate of Capitol Securities Management, or Capitol Securities Management, received compensation from the subject company for products or services during the past 12 months.

The subject company is not, or during the past 12 months, was not, a client of Capitol Securities Management's Investment Banking/Public Finance unit.



Other Disclosures

This report is not directed to, or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Capitol Securities or its affiliates to any registration or licensing requirement within such jurisdiction. The information presented in this report is provided to you for information purposes only and is not to be used or considered as an offer or the solicitation of an offer to sell or buy or subscribe for securities or other financial instruments. Capitol Securities may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. Capitol Securities will not treat recipients of this report as its customers by virtue of their receiving this report. The investments and services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. Capitol Securities does not advise on the tax consequences of investments and you are advised to contact an independent tax advisor. Information and opinions presented in this report have been obtained or derived from sources believed by Capitol Securities to be reliable, but Capitol Securities

makes no representation as to their accuracy or completeness. This report is not to be relied upon in substitution for the exercise of independent judgment. Capitol Securities may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by Capitol Securities and are subject to change without notice. The price, value of and income from any of the securities mentioned in this report can fall as well as rise.

For more information on this report, please contact us at 800.612.1484 or write to Capitol Securities, 100 Concourse Boulevard, Suite 101, Glen Allen, Virginia 23059